R
ReGenX Biosciences
A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy
About ReGenX Biosciences
REGENXBIO Inc. is a clinical-stage biotechnology company that has been a key player in the gene therapy field since its establishment in 2009. The company was founded through a collaboration between the biotechnology consultancy firm FoxKiser and the University of Pennsylvania, based on foundational gene therapy research from the lab of James M. Wilson, M.D., Ph.D. Key founders include Kenneth T. Mills and James Brown, both chemists who previously worked at IGEN International and Meso Scale Diagnostics. Allan Fox, a founding partner of FoxKiser with a background in law and public policy, was also instrumental in the company's formation. Mills served as the founding President and CEO for 15 years, leading the company through its Initial Public Offering in September 2015, which raised approximately $159.4 million, before transitioning to the role of Chairman of the Board in 2024.
The company's core business revolves around its proprietary NAV® Technology Platform, which is an adeno-associated virus (AAV) gene delivery system. This platform consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, and AAV9, which are engineered to be effective vehicles for delivering therapeutic genes into the body to treat a variety of diseases. REGENXBIO operates a bimodal business model. Initially focused on licensing, the company now generates revenue through multiple streams: royalties from licensees, collaboration agreements with pharmaceutical companies, and milestone payments. A prime example of its licensing success is Novartis' Zolgensma, a treatment for spinal muscular atrophy (SMA) that uses REGENXBIO's technology and provides a significant royalty stream. The company also enters into major collaborations, such as its partnership with AbbVie to develop treatments for retinal diseases and with Nippon Shinyaku for therapies targeting rare metabolic disorders like MPS I and MPS II.
In addition to out-licensing its technology, REGENXBIO develops its own pipeline of one-time gene therapy treatments, focusing on retinal, rare, and neurodegenerative diseases. Key product candidates include ABBV-RGX-314 for wet age-related macular degeneration (wet AMD) and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. The company is advancing these programs through late-stage clinical trials with a stated goal of bringing five new therapeutics to pivotal-stage or commercial status by 2025. The FDA's review for RGX-121 has a goal date set for early 2026. With end-to-end capabilities in research, clinical development, and manufacturing, REGENXBIO is positioned to address significant unmet medical needs across a spectrum of severe diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
ReGenX Biosciences in the Rockville ecosystem
The ReGenX Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
Fondazione Telethon
Series B and later12 investors entered at this stage
Brookside Capital
Venrock
F-Prime
Vivo Capital
Perceptive Advisors
Jennison Associates
Sectoral Asset Management- QLQVT Financial LP
Foresite Capital
Janus Capital Group
Frazier Healthcare Partners
HealthCare Royalty
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
82 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReGenX Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReGenX Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


